Cargando…

Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study

Background. sequential chemotherapy can maintain dose intensity and preclude cumulative toxicity by increasing drug diversity. Purpose. to investigate the toxicity and efficacy of the sequential regimen of gemcitabine followed by paclitaxel in first line advanced stage non-small cell lung cancer (NS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Surmont, V., Aerts, J. G. J. V., Tan, K. Y., Schramel, F., Vernhout, R., Hoogsteden, H. C., van Klaveren, R. J.
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2009
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2777239/ https://www.ncbi.nlm.nih.gov/pubmed/19920864 http://dx.doi.org/10.1155/2009/457418

Ejemplares similares

Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer
por: Cappuzzo, F, et al.
Publicado: (2005)

First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study
por: Tibaldi, C, et al.
Publicado: (2008)

Optical Detection of Preneoplastic Lesions of the Central Airways
por: van der Leest, C., et al.
Publicado: (2012)

A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment
por: Wachters, F M, et al.
Publicado: (2005)

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.
por: de Wit, R., et al.
Publicado: (1998)

The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – a non-randomized phase II clinical trial
por: Rutten, V. C., et al.
Publicado: (2023)

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours
por: Medley, L, et al.
Publicado: (2011)

Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials
por: Mossop, Helen, et al.
Publicado: (2021)

A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer
por: Suzuki, R, et al.
Publicado: (2006)

Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I–II trial
por: Stathopoulos, G P, et al.
Publicado: (2005)

Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer
por: Vriens, B. E. P. J., et al.
Publicado: (2017)

Block sequential adriamycin CMF – optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?
por: Cameron, D A, et al.
Publicado: (2002)

Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer
por: Sun, Sheng-Jie, et al.
Publicado: (2022)

A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer
por: Harries, M, et al.
Publicado: (2004)

Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer
por: Xu, Jian Ming, et al.
Publicado: (2006)

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
por: Weiss, J M, et al.
Publicado: (2019)

Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer
por: Passardi, Alessandro, et al.
Publicado: (2008)

Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study
por: Groen, Harry J. M., et al.
Publicado: (2019)

A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer
por: Kang, H J, et al.
Publicado: (2008)

Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer
por: Schønnemann, K R, et al.
Publicado: (2008)

First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial
por: Arrieta, Ó, et al.
Publicado: (2012)

Peptides from the Variable Region of Specific Antibodies Are Shared among Lung Cancer Patients
por: de Costa, Dominique, et al.
Publicado: (2014)

Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
por: Sørensen, J B, et al.
Publicado: (2008)

Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
por: Ulahannan, Susanna V, et al.
Publicado: (2011)

A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer
por: Graziano, F, et al.
Publicado: (2003)

Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy
por: Rose, Tracy L., et al.
Publicado: (2018)

Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
por: Westerink, Lotte, et al.
Publicado: (2020)

Disease control and objective responsive rates in randomized phase II trials evaluating non-first-line chemotherapy for non-small cell lung cancer: a systematic review of 74 trials
por: Matsumoto, Hiromi, et al.
Publicado: (2021)

Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC – a phase II trial
por: Babiak, A, et al.
Publicado: (2007)

Decision aids for second-line palliative chemotherapy: a randomised phase II multicentre trial
por: Oostendorp, Linda J. M., et al.
Publicado: (2017)

Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer
por: Galli, L, et al.
Publicado: (2007)

Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
por: Briasoulis, Alexandros, et al.
Publicado: (2022)

BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC)
por: Glynne-Jones, R., et al.
Publicado: (2018)

Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer
por: Ferrario, Cristiano, et al.
Publicado: (2016)

A Bitter Pill to Swallow: Pseudoachalasia Secondary to Oesophageal Deviation Resulting from Mediastinal Shift and Left Atrial Enlargement after Left Lower Lobectomy
por: Surmont, Magali M.V.P., et al.
Publicado: (2020)

Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease)
por: Phernambucq, E C J, et al.
Publicado: (2006)

Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma
por: Plummer, R, et al.
Publicado: (2013)

Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study
por: Douillard, J Y, et al.
Publicado: (2001)

Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer.
por: Pujol, J. L., et al.
Publicado: (1994)

Ultra-Wide Band Non-reciprocity through Sequentially-Switched Delay Lines
por: Biedka, Mathew M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n81sgkukukjktht27fl77c2p2f